IPO registrations (S-1, F-1) · Registrants
Virpax Pharmaceuticals, Inc.
- SEC CIK
- 1708331 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2020-10-09, last 2025-03-25; 6 initial registrations, 14 amendments
- Outcome
- Final prospectus filed 2021-02-18; declared effective 2021-02-16
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1055 WESTLAKES DRIVE, SUITE 300, Berwyn, PA 19312
- EIN
- 82-1510982
- EDGAR entity type
- operating
- Insiders and CEO pay
- Virpax Pharmaceuticals, Inc. on the corporate pages
On this site
- Business registration: Virpax Pharmaceuticals, Inc. Fuzzy (name and state)
- Form D issuer: Virpax Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- Lobbying client: VIRPAX PHARMACEUTICALS Fuzzy (name and state)
- SEC filer: Virpax Pharmaceuticals, Inc. EXACT (CIK (EXACT))
Filings 32
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-10-09 | S-1 | S-1 (registration) | Virpax Pharmaceuticals, Inc. | 0001213900-20-030825 ↗ |
| 2020-11-20 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001213900-20-038528 ↗ |
| 2020-12-16 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001213900-20-043072 ↗ |
| 2021-01-08 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001213900-21-001231 ↗ |
| 2021-02-02 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001213900-21-005984 ↗ |
| 2021-02-16 | S-1MEF | S-1MEF (added securities) | Virpax Pharmaceuticals, Inc. | 0001213900-21-009773 ↗ |
| 2021-02-16 | EFFECT | EFFECT (declared effective) | Virpax Pharmaceuticals, Inc. | 9999999995-21-000649 ↗ |
| 2021-02-18 | 424B4 | 424B4 (final prospectus) | Virpax Pharmaceuticals, Inc. | 0001213900-21-010341 ↗ |
| 2021-09-09 | S-1 | S-1 (registration) | Virpax Pharmaceuticals, Inc. | 0001213900-21-047233 ↗ |
| 2021-09-14 | EFFECT | EFFECT (declared effective) | Virpax Pharmaceuticals, Inc. | 9999999995-21-003539 ↗ |
| 2021-09-15 | 424B4 | 424B4 (final prospectus) | Virpax Pharmaceuticals, Inc. | 0001213900-21-048233 ↗ |
| 2022-10-18 | EFFECT | EFFECT (declared effective) | Virpax Pharmaceuticals, Inc. | 9999999995-22-003078 ↗ |
| 2024-04-18 | S-1 | S-1 (registration) | Virpax Pharmaceuticals, Inc. | 0001213900-24-034117 ↗ |
| 2024-04-26 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001213900-24-036727 ↗ |
| 2024-05-02 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001213900-24-038733 ↗ |
| 2024-05-13 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001213900-24-042447 ↗ |
| 2024-05-14 | EFFECT | EFFECT (declared effective) | Virpax Pharmaceuticals, Inc. | 9999999995-24-001527 ↗ |
| 2024-05-16 | 424B4 | 424B4 (final prospectus) | Virpax Pharmaceuticals, Inc. | 0001213900-24-044286 ↗ |
| 2024-07-29 | S-1 | S-1 (registration) | Virpax Pharmaceuticals, Inc. | 0001013762-24-002110 ↗ |
| 2024-08-13 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001213900-24-067945 ↗ |
| 2024-10-18 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001731122-24-001622 ↗ |
| 2024-10-28 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001731122-24-001662 ↗ |
| 2024-11-07 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001731122-24-001742 ↗ |
| 2024-11-12 | EFFECT | EFFECT (declared effective) | Virpax Pharmaceuticals, Inc. | 9999999995-24-003447 ↗ |
| 2024-11-13 | 424B4 | 424B4 (final prospectus) | Virpax Pharmaceuticals, Inc. | 0001731122-24-001773 ↗ |
| 2024-12-30 | S-1 | S-1 (registration) | Virpax Pharmaceuticals, Inc. | 0001731122-24-002064 ↗ |
| 2025-01-15 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001731122-25-000082 ↗ |
| 2025-01-17 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001731122-25-000092 ↗ |
| 2025-01-27 | EFFECT | EFFECT (declared effective) | Virpax Pharmaceuticals, Inc. | 9999999995-25-000203 ↗ |
| 2025-01-28 | 424B4 | 424B4 (final prospectus) | Virpax Pharmaceuticals, Inc. | 0001731122-25-000131 ↗ |
| 2025-03-17 | S-1 | S-1 (registration) | Virpax Pharmaceuticals, Inc. | 0001731122-25-000401 ↗ |
| 2025-03-25 | S-1/A | S-1/A (amendment) | Virpax Pharmaceuticals, Inc. | 0001731122-25-000439 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bruce Gerald W | Director; Director,Officer; Officer | Chief Executive Officer; EVP, Commercial Operations | 6 | 2021–2024 | |
| Chipman Christopher Michael | Officer | Chief Financial Officer | 5 | 2021–2023 | |
| Floyd Eric | Director | 6 | 2021–2024 | ||
| Gudin Jeffrey | Director,Officer | Chief Medical Officer | 5 | 2021–2023 | |
| JACOB GARY S | Director | 4 | 2021–2022 | ||
| Jambulingam Thani | Director | 6 | 2021–2024 | ||
| Mack Anthony P. | Director,Officer; Director,Officer,TenPercentOwner | Chief Executive Officer | 8 | 2021–2023 | |
| Sendrow Jerrold | Director | 7 | 2021–2024 | ||
| Singh Vanila | Director | 5 | 2021–2024 | ||
| Virpax Pharmaceuticals LLC | TenPercentOwner | 1 | 2021 | ||
| Dubin Michael F | Director | 5 | 2021–2024 | ||
| Ruskin Barbara | Director | 3 | 2023–2024 | ||
| Shah Vinay | Officer | Chief Financial Officer | 4 | 2023–2024 | |
| Mathias Sheila | Officer | Chief Scientific Officer | 2 | 2023–2024 | |
| Dhaliwal Jatinder | Director | 2 | 2024 | ||
| Herman Gary L | Director | 2 | 2024 | ||
| Field Katharyn | Director | 2 | 2024 | ||
| Su Judy | Director | 1 | 2024 | ||
| Randhawa Esha | Director | 1 | 2024 | ||
| Chaudhry Usama | Officer | Chief Financial Officer | 1 | 2025 | |
| Panis Jaydriane | Director | 1 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-07-12 | Virpax Pharmaceuticals, Inc. | Pharmaceuticals | $2,500,000 | $2,500,000 | 1 | 1 |
| 2018-04-05 | Virpax Pharmaceuticals, Inc. | Pharmaceuticals | $3,000,000 | $1,379,000 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.